
Anima Biotech is a TechBio pioneer transforming target and drug discovery with its Visual Biology platform, Lightning.AI. This platform utilizes neural networks trained on over 2 billion images to identify disease-driving pathways from cell images, enabling the discovery of novel targets and drugs. Lightning.AI operates as a continuous loop between a Computational AI and an Experimental AI, integrating omics, literature, and imaging data to discover druggable targets and develop tailored small molecule mRNA biology modulators. The company has strategic partnerships with AbbVie, Takeda, and Lilly, and boasts 20 pipeline programs across oncology, neurology, immunology, and rare diseases, validating its unique approach to seeing and understanding disease biology for drug discovery.

Anima Biotech is a TechBio pioneer transforming target and drug discovery with its Visual Biology platform, Lightning.AI. This platform utilizes neural networks trained on over 2 billion images to identify disease-driving pathways from cell images, enabling the discovery of novel targets and drugs. Lightning.AI operates as a continuous loop between a Computational AI and an Experimental AI, integrating omics, literature, and imaging data to discover druggable targets and develop tailored small molecule mRNA biology modulators. The company has strategic partnerships with AbbVie, Takeda, and Lilly, and boasts 20 pipeline programs across oncology, neurology, immunology, and rare diseases, validating its unique approach to seeing and understanding disease biology for drug discovery.